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LESSONS LEARNED
• The addition of the heat shock protein 27 (Hsp27)-targeting antisense oligonucleotide, apatorsen, to a standard first-line
chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer.
• Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further
investigation.
ABSTRACT
Background. This randomized, double-blinded, phase II trial
evaluated the efficacy of gemcitabine/nab-paclitaxel plus either
apatorsen, an antisense oligonucleotide targeting heat shock
protein 27 (Hsp27) mRNA, or placebo in patients with meta-
static pancreatic cancer.
Methods. Patients were randomized 1:1 to Arm A (gemcita-
bine/nab-paclitaxel plus apatorsen) or Arm B (gemcitabine/
nab-paclitaxel plus placebo). Treatment was administered in 28-
day cycles, with restaging every 2 cycles, until progression or
intolerable toxicity. Serum Hsp27 levels were analyzed at base-
line and on treatment. The primary endpoint was overall sur-
vival (OS).
Results. One hundred thirty-two patients were enrolled, 66 per
arm. Cytopenias and fatigue were the most frequent grade 3/4
treatment-related adverse events for both arms. Median
progression-free survival (PFS) and OS were 2.7 and 5.3
months, respectively, for arm A, and 3.8 and 6.9 months,
respectively, for arm B. Objective response rate was 18% for
both arms. Patients with high serum level of Hsp27 represented
a poor-prognosis subgroup who may have derived modest ben-
efit from addition of apatorsen.
Conclusion. Addition of apatorsen to chemotherapy does not
improve outcomes in unselected patients with metastatic
pancreatic cancer in the first-line setting, although a trend
toward prolonged PFS and OS in patients with high baseline
serum Hsp27 suggests this therapy may warrant further evalua-
tion in this subgroup.The Oncologist 2017;22:1427–e129
DISCUSSION
Heat shock protein 27 (Hsp27) is a protein chaperone whose
expression is induced by cytotoxic chemotherapy, as well as
other cell stressors such as hyperthermia, oxidative stress,
and radiation, resulting in cytoprotection against these insults
[1, 2]. Various malignancies, including pancreatic adenocarci-
noma, overexpress Hsp27 [3]; furthermore, preclinical studies
show that Hsp27 expression may play a role in the resistance of
pancreatic cancer cell lines to gemcitabine [4–6]. Thus, inhibi-
ting Hsp27 activity represents a viable therapeutic strategy in
this disease. Apatorsen, an antisense oligonucleotide designed
to bind to Hsp27 mRNA and block its translation into functional
protein, offers one such approach [7].
On these bases, we performed a randomized phase II
trial to compare the safety and efficacy of gemcitabine and
nab-paclitaxel in combination with either apatorsen or
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Clinical Trial Results
placebo in the first-line setting for patients with metastatic
pancreatic cancer. The planned sample size of 130 provided
80% power to detect a difference in median survival of 8.5
versus 13.4 months (hazard ratio [HR] for death, 0.634; 1-
sided a5 0.1).
Although the incidence of toxicities did not differ signifi-
cantly between the two treatment arms (most common
treatment-related toxicities of all grades on both arms
included fatigue, cytopenias, and gastrointestinal symp-
toms), the addition of apatorsen to chemotherapy did not
produce any improvement in clinical outcomes in the intent-
to-treat population. The objective response rate (ORR) was
identical (18%) on both treatment arms, whereas patients
on the apatorsen arm fared numerically worse in terms of
both progression-free survival (PFS) and overall survival (OS)
when compared with patients on the placebo arm, although
these differences were not statistically significant (median
PFS, 2.7 vs. 3.8 months, respectively [p5 .92; HR 1.0];
median OS, 5.3 vs. 6.9 months, respectively [p5 .62; HR
1.1]). Notably, the survival outcomes for patients on both
arms of this study were considerably inferior to those
observed on the gemcitabine/nab-paclitaxel arm from the
phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial
(MPACT) study [8], for unclear reasons.
The only subgroup for whom a potential benefit of apa-
torsen could be identified was those patients with high serum
levels of Hsp27, a marker associated with a very poor prognosis
overall (median PFS for patients with high baseline serum
Hsp27 levels, 3.3 vs. 0.9 months for apatorsen vs. placebo,
respectively [HR 0.38], median OS 3.3 vs. 1.0 months [HR
0.59]). However, the number of subjects who fit into this cate-
gory was too small, representing only 14% of the entire study
population, to draw any definitive conclusions.
In summary, the addition of apatorsen to a standard
combination chemotherapy regimen in the first-line set-
ting did not result in improvement in survival or other clin-
ically relevant endpoints in patients with metastatic
pancreatic cancer. Although further studies of this agent in
unselected patients do not appear to be indicated, the
findings from this trial do hint at the possible prognostic
and predictive value of serum Hsp27 that may warrant fur-
ther investigation.
TRIAL INFORMATION
Disease Metastatic pancreatic adenocarcinoma
Stage of Disease/Treatment Metastatic/advanced
Prior Therapy None
Type of Study – 1 Phase II
Type of Study – 2 Randomized
PFS p5 0.92, HR: 1.0
OS p5 0.62, HR: 1.1
Primary Endpoint Overall survival
Secondary Endpoint Progression-free survival
Secondary Endpoint Toxicity
Investigator’s Analysis Feasible, possibly effective in patients
with high Hsp27 serum levels
DRUG INFORMATION FOR PHASE II CONTROL
Drug 1
Generic/Working name Nab-paclitaxel
Trade name Abraxane
Company name Celgene
Table 1. Median PFS and OS stratified by heat shock protein 27 levels
Median PFS, months (95% CI) Median OS, months (95% CI)
N
Nab-paclitaxel/
gemcitabine1
apatorsen
Nab-paclitaxel/
gemcitabine1
placebo
PFS
hazard
ratio
Nab-paclitaxel/
gemcitabine 1
apatorsen
Nab-paclitaxel/
gemcitabine 1
placebo
OS hazard
ratio
Low/
normal
Hsp27
102 2.9 (2.2, 4.0) 4.1 (3.1, 5.7) 1.178 (0.902, 1.539) 6.0 (3.2, 7.2) 9.0 (6.3, 11.2) 1.243 (0.813, 1.901)
High
Hsp27
18 3.3 (0.3, 11.8) 0.9 (0.4, 1.4) 0.381 (0.120, 1.208) 3.3 (0.3, 11.8) 1.0 (0.6, 14.0) 0.587 (0.195, 1.770)
Abbreviations: CI, confidence interval; Hsp27, heat shock protein 27; OS, overall survival; PFS, progression-free survival.
Drug type Other
1428 Apatorsen in Metastatic Pancreatic Cancer
Oc AlphaMed Press 2017
Drug class Microtubule-targeting agent
Dose 125 milligrams (mg) per square meter (m2)
Route IV
Schedule of administration Placebo days 1, 8, 15, and 22 of a 28-day cycle
Nab-paclitaxel and gemcitabine days 1, 8,
and 15 of a 28-day cycle
Drug 2
Generic/Working name Gemcitabine
Trade name Gemzar
Company name Eli Lilly
Drug type Other
Drug class Antimetabolite
Dose 1,000 mg/m2
Route IV
Schedule of administration Placebo days 1, 8, 15, and 22 of a 28-day cycle
Nab-paclitaxel and gemcitabine days 1, 8, and
15 of a 28-day cycle
DRUG INFORMATION FOR PHASE II EXPERIMENTAL
Drug 1
Generic/Working name Apatorsen
Trade name Not applicable
Company name OncoGenex
Drug type Other
Drug class Antisense oligonucleotide
Dose 600 mg per flat dose
Route IV
Schedule of administration Apatorsen days 1, 8, 15, and 22 of a 28-day cycle
Nab-paclitaxel and gemcitabine days 1, 8, and
15 of a 28-day cycle
Drug 2
Generic/Working name Nab-paclitaxel
Trade name Abraxane
Company name Celgene
Drug type Other
Drug class Microtubule-targeting agent
Dose 125 mg/m2
Schedule of administration Apatorsen days 1, 8, 15, and 22 of a 28-day cycle
Nab-paclitaxel and gemcitabine days 1, 8, and 15
of a 28-day cycle pfof
Drug 3
Generic/Working name Gemcitabine
Trade name Gemzar
Company name Eli Lilly
Drug type Other
Drug class Antimetabolite
Dose 1,000 mg/m2
Route IV
Schedule of administration Apatorsen 1, 8, 15, and 22 of a 28-day cycle
Nab-paclitaxel and gemcitabine days 1, 8, and
15 of a 28-day cycle
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PATIENT CHARACTERISTICS FOR PHASE II CONTROL
Number of Patients, Male 38
Number of Patients, Female 28
Stage IV
Age Median (range): 65.5 (47–83)
Number of Prior Systemic Therapies Median (range): None
Performance Status ECOG 0 — 32
1 — 32
2 —
3 —
Unknown — 2
Cancer Types or Histologic Subtypes CA19-9 levels 90 U/mL 11
CA19-9 levels >90 U/mL 54
CA19-9 levels Unknown 1
Hsp27 expression high 11
Hsp27 expression low 47
Hsp27 expression Unknown 8
PATIENT CHARACTERISTICS FOR PHASE II EXPERIMENTAL
Number of Patients, Male 37
Number of Patients, Female 29
Stage IV
Age Median (range): 66.5 (39–82)
Number of Prior Systemic Therapies Median (range): None
Performance Status: ECOG 0 — 30
1 — 36
2 —
3 —
Unknown —
Cancer Types or Histologic Subtypes CA19-9 levels 90 U/mL 18
CA19-9 levels >90 U/mL 47
CA19-9 levels unknown 1
Hsp27 expression high 7
Hsp27 expression low 55
Hsp27 expression unknown 4
PRIMARYASSESSMENT METHOD FOR PHASE II CONTROL
Assessment: Total Patient Population: Overall Survival
Number of patients screened 66
Number of patients enrolled 66
Number of patients evaluable for toxicity 63
Number of patients evaluated for efficacy 66
Evaluation method RECIST 1.1
Response assessment CR n5 0 (0%)
Response assessment PR n5 12 (18%)
Response assessment SD n5 21 (32%)
Response assessment PD n5 18 (28%)
Response assessment OTHER n5 15 (22%)
(Median) duration assessments PFS 3.8 months
(Median) duration assessments OS 6.9 months
Kaplan-Meier time units months
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Waterfall plot demonstrating best objective response in response-evaluable subjects on control arm.
Time of scheduled
assessment and/or
time of event
No. progressed
(or deaths)
No.
censored
Percent at start of
evaluation period Kaplan-Meier %
No. at next
evaluation/No.
at risk
0.03 0 1 100.00 100.00 65
0.13 1 0 100.00 98.46 64
0.30 1 0 98.46 96.92 63
0.43 1 0 96.92 95.38 62
0.62 1 0 95.38 93.85 61
0.76 1 0 93.85 92.31 60
0.85 1 0 92.31 90.77 59
0.89 1 0 90.77 89.23 58
0.95 1 0 89.23 87.69 57
1.05 1 0 87.69 86.15 56
1.12 1 0 86.15 84.62 55
1.35 0 1 84.62 84.62 54
1.38 1 0 84.62 83.05 53
1.84 1 0 83.05 81.48 52
1.97 1 0 81.48 79.91 51
2.23 0 1 79.91 79.91 50
2.53 1 0 79.91 78.32 49
2.92 1 0 78.32 76.72 48
3.06 1 0 76.72 75.12 47
3.22 1 0 75.12 73.52 46
3.45 1 0 73.52 71.92 45
3.52 1 0 71.92 70.32 44
3.75 1 0 70.32 68.73 43
4.11 1 0 68.73 67.13 42
4.37 0 1 67.13 67.13 41
4.47 1 0 67.13 65.49 40
4.73 1 0 65.49 63.85 39
5.85 1 0 63.85 62.22 38
6.14 1 0 62.22 60.58 37
6.24 1 0 60.58 58.94 36
6.34 1 0 58.94 57.30 35
6.37 1 0 57.30 55.67 34
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6.60 1 0 55.67 54.03 33
6.83 1 0 54.03 52.39 32
6.93 2 0 52.39 49.12 30
7.52 2 0 49.12 45.84 28
7.98 1 0 45.84 44.21 27
8.11 1 0 44.21 42.57 26
8.21 1 0 42.57 40.93 25
9.00 1 0 40.93 39.29 24
9.26 1 0 39.29 37.66 23
9.30 1 0 37.66 36.02 22
9.33 1 0 36.02 34.38 21
9.66 0 1 34.38 34.38 20
10.02 1 0 34.38 32.66 19
10.12 0 1 32.66 32.66 18
10.91 1 0 32.66 30.85 17
11.07 1 0 30.85 29.03 16
11.24 1 0 29.03 27.22 15
11.53 1 0 27.22 25.41 14
11.93 1 0 25.41 23.59 13
12.22 1 0 23.59 21.78 12
12.94 1 0 21.78 19.96 11
14.00 1 0 19.96 18.15 10
14.75 1 0 18.15 16.33 9
14.95 0 1 16.33 16.33 8
15.70 0 1 16.33 16.33 7
18.17 1 0 16.33 14.00 6
18.53 1 0 14.00 11.67 5
18.99 1 0 11.67 9.33 4
21.32 0 1 9.33 9.33 3
22.14 1 0 9.33 6.22 2
22.87 1 0 6.22 3.11 1
25.76 0 1 3.11 0.00 0
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Assessment: Total Patient Population: Progression-Free Survival
Number of patients screened 66
Number of patients enrolled 66
Number of patients evaluable for toxicity 63
Number of patients evaluated for efficacy 66
Evaluation method RECIST 1.1
Response assessment CR n5 0 (0%)
Response assessment PR n5 12 (18%)
Response assessment SD n5 21 (32%)
Response assessment PD n5 18 (28%)
Response assessment OTHER n5 15 (22%)
(Median) duration assessments PFS 3.8 months
(Median) duration assessments OS 6.9 months
Kaplan-Meier time units months
Time of scheduled
assessment and/or
time of event
No. progressed
(or deaths)
No.
censored
Percent at start of
evaluation period Kaplan-Meier %
No. at next
evaluation/No.
at risk
0.03 0 3 100.00 100.00 63
0.13 1 0 100.00 98.41 62
0.30 1 0 98.41 96.83 61
0.43 1 0 96.83 95.24 60
0.62 2 0 95.24 92.06 58
0.76 1 0 92.06 90.48 57
0.85 1 0 90.48 88.89 56
0.89 1 0 88.89 87.30 55
0.95 1 0 87.30 85.71 54
1.05 1 0 85.71 84.13 53
1.38 1 0 84.13 82.54 52
1.68 1 0 82.54 80.95 51
1.84 1 0 80.95 79.37 50
1.87 1 0 79.37 77.78 49
1.97 2 0 77.78 74.60 47
2.07 1 0 74.60 73.02 46
2.10 3 0 73.02 68.25 43
2.14 1 0 68.25 66.67 42
2.20 0 1 66.67 66.67 41
2.23 2 0 66.67 63.41 39
2.27 2 0 63.41 60.16 37
2.33 1 0 60.16 58.54 36
2.53 1 0 58.54 56.91 35
3.06 1 0 56.91 55.28 34
3.22 2 0 55.28 52.03 32
3.75 1 0 52.03 50.41 31
3.84 1 0 50.41 48.78 30
3.91 2 0 48.78 45.53 28
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4.01 1 0 45.53 43.90 27
4.07 1 0 43.90 42.28 26
4.11 1 0 42.28 40.65 25
4.14 1 0 40.65 39.02 24
4.67 1 0 39.02 37.40 23
4.73 1 0 37.40 35.77 22
4.80 1 0 35.77 34.15 21
5.03 1 0 34.15 32.52 20
5.65 1 0 32.52 30.89 19
5.85 1 0 30.89 29.27 18
6.01 1 0 29.27 27.64 17
6.08 0 1 27.64 27.64 16
6.18 1 0 27.64 25.91 15
6.24 1 0 25.91 24.19 14
6.93 1 0 24.19 22.46 13
7.36 2 0 22.46 19.00 11
7.89 1 0 19.00 17.28 10
7.98 1 0 17.28 15.55 9
9.40 1 0 15.55 13.82 8
9.86 1 0 13.82 12.09 7
11.07 1 0 12.09 10.37 6
11.56 1 0 10.37 8.64 5
11.79 1 0 8.64 6.91 4
12.22 1 0 6.91 5.18 3
12.78 1 0 5.18 3.46 2
15.67 1 0 3.46 1.73 1
24.51 0 1 1.73 0.00 0
e122 Apatorsen in Metastatic Pancreatic Cancer
Oc AlphaMed Press 2017
PRIMARYASSESSMENT METHOD FOR PHASE II EXPERIMENTAL
Assessment: Total Patient Population: Overall Survival
Number of patients screened 66
Number of patients enrolled 66
Number of patients evaluable for toxicity 64
Number of patients evaluated for efficacy 66
Evaluation method RECIST 1.1
Response assessment CR n5 0 (0%)
Response assessment PR n5 12 (18%)
Response assessment SD n5 16 (24%)
Response assessment PD n5 21 (32%)
Response assessment OTHER n5 17 (26%)
(Median) duration assessments PFS 2.7 months
(Median) duration assessments OS 5.3
Kaplan-Meier time units months
Time of scheduled
assessment and/or
time of event
No. progressed
(or deaths)
No.
censored
Percent at start of
evaluation period Kaplan-Meier %
No. at next
evaluation/No.
at risk
0.07 1 0 100.00 98.48 65
0.26 1 0 98.48 96.97 64
0.46 1 0 96.97 95.45 63
0.79 1 0 95.45 93.94 62
0.82 1 0 93.94 92.42 61
0.85 1 0 92.42 90.91 60
0.89 2 0 90.91 87.88 58
0.99 1 0 87.88 86.36 57
1.18 1 0 86.36 84.85 56
1.22 1 0 84.85 83.33 55
1.31 0 1 83.33 83.33 54
1.38 1 0 83.33 81.79 53
1.48 1 0 81.79 80.25 52
Waterfall plot demonstrating best objective response in response-evaluable subjects on experimental arm.
Ko, Murphy, Peyton et al. e123
www.TheOncologist.com Oc AlphaMed Press 2017
1.51 1 0 80.25 78.70 51
1.68 1 0 78.70 77.16 50
1.87 1 0 77.16 75.62 49
2.33 1 0 75.62 74.07 48
2.46 1 0 74.07 72.53 47
2.50 2 0 72.53 69.44 45
2.66 1 0 69.44 67.90 44
2.89 1 0 67.90 66.36 43
3.02 1 0 66.36 64.81 42
3.22 2 0 64.81 61.73 40
3.25 1 0 61.73 60.19 39
3.55 1 0 60.19 58.64 38
3.65 1 0 58.64 57.10 37
4.17 1 0 57.10 55.56 36
4.37 2 0 55.56 52.47 34
4.83 1 0 52.47 50.93 33
5.29 1 0 50.93 49.38 32
5.45 1 0 49.38 47.84 31
5.49 1 0 47.84 46.30 30
6.05 1 1 46.30 44.70 28
6.18 1 0 44.70 43.10 27
6.24 1 0 43.10 41.51 26
6.80 1 0 41.51 39.91 25
7.03 1 0 39.91 38.31 24
7.16 2 0 38.31 35.12 22
8.21 1 0 35.12 33.52 21
9.26 1 0 33.52 31.93 20
9.92 1 0 31.93 30.33 19
10.48 1 0 30.33 28.74 18
11.14 1 0 28.74 27.14 17
11.60 1 0 27.14 25.54 16
11.70 1 0 25.54 23.95 15
11.83 1 0 23.95 22.35 14
11.96 1 0 22.35 20.75 13
12.29 1 0 20.75 19.16 12
15.74 1 0 19.16 17.56 11
16.26 1 0 17.56 15.96 10
16.59 1 0 15.96 14.37 9
17.05 0 1 14.37 14.37 8
17.48 0 1 14.37 14.37 7
17.81 1 0 14.37 12.32 6
17.87 0 1 12.32 12.32 5
18.00 0 1 12.32 12.32 4
20.47 1 0 12.32 9.24 3
22.34 0 1 9.24 9.24 2
24.87 0 1 9.24 9.24 1
27.83 1 0 9.24 0.00 0
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Assessment: Total Patient Population: Progression-Free Survival
Number of patients screened 66
Number of patients enrolled 66
Number of patients evaluable for toxicity 64
Number of patients evaluated for efficacy 66
Evaluation method RECIST 1.1
Response assessment CR n5 0 (0%)
Response assessment PR n5 12 (18%)
Response assessment SD n5 16 (24%)
Response assessment PD n5 21 (32%)
Response assessment OTHER n5 17 (26%)
Kaplan-Meier time units months
Time of scheduled
assessment and/or
time of event
No. progressed
(or deaths)
No.
censored
Percent at start of
evaluation period Kaplan-Meier %
No. at next
evaluation/No.
at risk
0.03 0 1 100.00 100.00 65
0.07 1 0 100.00 98.46 64
0.26 1 0 98.46 96.92 63
0.46 1 0 96.92 95.38 62
0.66 1 0 95.38 93.85 61
0.79 1 0 93.85 92.31 60
0.82 1 0 92.31 90.77 59
0.85 1 0 90.77 89.23 58
0.89 2 0 89.23 86.15 56
0.99 1 0 86.15 84.62 55
1.18 1 0 84.62 83.08 54
1.22 1 0 83.08 81.54 53
1.38 1 0 81.54 80.00 52
1.51 1 0 80.00 78.46 51
1.54 1 0 78.46 76.92 50
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1.68 1 0 76.92 75.38 49
1.77 1 0 75.38 73.85 48
1.81 1 0 73.85 72.31 47
1.87 1 0 72.31 70.77 46
1.97 1 0 70.77 69.23 45
2.07 1 0 69.23 67.69 44
2.10 1 0 67.69 66.15 43
2.14 2 0 66.15 63.08 41
2.17 1 0 63.08 61.54 40
2.23 1 0 61.54 60.00 39
2.30 1 0 60.00 58.46 38
2.33 1 0 58.46 56.92 37
2.40 1 0 56.92 55.38 36
2.43 1 0 55.38 53.85 35
2.46 1 0 53.85 52.31 34
2.50 1 0 52.31 50.77 33
2.66 1 0 50.77 49.23 32
3.22 1 0 49.23 47.69 31
3.25 1 0 47.69 46.15 30
3.45 1 0 46.15 44.62 29
3.55 1 0 44.62 43.08 28
3.65 1 0 43.08 41.54 27
3.68 1 0 41.54 40.00 26
3.71 1 0 40.00 38.46 25
3.75 1 0 38.46 36.92 24
3.98 1 0 36.92 35.38 23
4.17 1 0 35.38 33.85 22
4.73 1 0 33.85 32.31 21
5.45 1 0 32.31 30.77 20
5.52 1 0 30.77 29.23 19
5.78 1 0 29.23 27.69 18
5.88 1 1 27.69 26.06 16
6.14 1 0 26.06 24.43 15
6.18 1 0 24.43 22.81 14
6.24 1 0 22.81 21.18 13
7.66 1 0 21.18 19.55 12
8.31 0 1 19.55 19.55 11
8.90 1 0 19.55 17.77 10
9.79 0 1 17.77 17.77 9
10.05 0 1 17.77 17.77 8
11.63 1 0 17.77 15.55 7
11.83 1 0 15.55 13.33 6
12.29 1 0 13.33 11.11 5
13.60 2 0 11.11 6.66 3
13.93 1 0 6.66 4.44 2
14.52 1 0 4.44 2.22 1
15.01 1 0 2.22 0.00 0
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ADVERSE EVENTS
Patients, n (%)
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Total
Hematologic
Anemia 1 (8%) 1 (8%) 0 0 2 (17%)
Thrombocytopenia 1 (8%) 1 (8%) 0 0 2 (17%)
Leukopenia 1 (8%) 0 0 0 1 (8%)
Nonhematologic
Nausea 3 (25%) 5 (42%) 0 0 8 (67%)
Diarrhea 3 (25%) 4 (33%) 0 0 7 (58%)
Fatigue 3 (25%) 2 (17%) 0 0 5 (42%)
Vomiting 3 (25%) 2 (17%) 0 0 5 (42%)
Mucosal inflammation 1 (8%) 2 (17%) 1 (8%) 0 3 (25%)
Stomatitis 2 (17%) 0 0 0 3 (25%)
Decreased appetite 2 (17%) 0 0 0 2 (17%)
Hypokalemia 0 0 2 (17%) 0 2 (17%)
Constipation 1 (8%) 0 0 0 1 (8%)
Dehydration 0 1 (8%) 0 0 1 (8%)
Dysgeusia 0 1 (8%) 0 0 1 (8%)
Dysphagia 1 (8%) 0 0 0 1 (8%)
Fall 0 1 (8%) 0 0 1 (8%)
Hyperglycemia 0 0 1 (8%) 0 1 (8%)
Hypersensitivity 0 0 1 (8%) 0 1 (8%)
Hypomagnesemia 1 (8%) 0 0 0 1 (8%)
Insomnia 1 (8%) 0 0 0 1 (8%)
Myalgia 1 (8%) 0 0 0 1 (8%)
Peripheral neuropathy 1 (8%) 0 0 0 1 (8%)
Peripheral edema 0 1 (8%) 0 0 1 (8%)
Peripheral embolism 0 1 (8%) 0 0 1 (8%)
Pruritus 1 (8%) 0 0 0 1 (8%)
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ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Pharmacokinetics/Pharmacodynamics Correlative endpoints not met
Investigator’s Assessment Feasible, possibly effective in patients with high
Hsp27 serum levels
Pancreatic adenocarcinoma is expected to rise to the sec-
ond leading cause of cancer-related mortality in the U.S. by the
end of this decade [9]. Systemic therapy represents the main-
stay of treatment for patients with advanced or metastatic dis-
ease, for whom two combination chemotherapy regimens
have emerged as front-line standards of care: gemcitabine plus
nab-paclitaxel [8], and FOLFIRINOX (5-fluorouracil, leucovorin,
irinotecan, and oxaliplatin) [10]. However, despite these recent
improvements in available cytotoxic therapies, overall progno-
sis in this disease remains very poor; for example, in the phase
III MPACT trial leading to the approval of nab-paclitaxel for met-
astatic pancreatic cancer, the median survival for patients
receiving the combination of gemcitabine plus nab-paclitaxel
was only 8.5 months, representing a statistically significant but
relatively modest absolute improvement of 1.8 months when
compared with single-agent gemcitabine [8]. Clearly, novel
drugs with unique mechanisms of action warrant further
exploration.
Molecularly targeted therapies that have been approved
for use in clinical oncology include monoclonal antibodies and
small molecule inhibitors, particularly tyrosine kinase inhibitors.
Unfortunately, many potential therapeutic targets are not ame-
nable to these specific pharmacologic approaches, highlighting
the importance of developing alternative strategies, including
agents that can disrupt these targets at the gene expression
level. Antisense oligonucleotides (ASOs), which are chemically
modified stretches of single-strand DNA complementary to the
mRNA regions of a target gene that inhibit translation by form-
ing RNA/DNA duplexes, represent one such approach to specifi-
cally prevent translation of functionally relevant genes.
Apatorsen, a 2’-methoxyethyl oligonucleotide with phos-
phorothiolated internucleotide linkages, is designed to bind to
heat shock protein 27 (Hsp27) mRNA and prevent translation
into a functional protein. Targeting this specific heat shock pro-
tein represents an attractive therapeutic option, because
Hsp27 can potentially affect multiple pathways implicated in
cancer progression and resistance, as opposed to targeting a
single pathway, a strategy that might have limited benefits in
the face of the redundant signaling pathways and significant
tumor heterogeneity. For example, overexpression of Hsp27 in
cancer cells is induced by cytotoxic chemotherapy, as well as
other cell stressors including hyperthermia, oxidative stress,
and radiation, resulting in cytoprotection against these insults
[1, 2]. Furthermore, Hsp27 serves to stabilize mutated or inap-
propriately activated oncoproteins that contribute to the initia-
tion, growth, andmetastasis of human cancers [2, 11].
The phase I dose-escalation study of apatorsen in patients
with castration-resistant prostate cancer and other advanced
cancers showed evidence of monotherapy activity as demon-
strated by decline in tumor markers and circulating tumor cells,
as well as stable measurable disease in 12 of 42 patients [12].
Further evaluation of apatorsen has been pursued in combina-
tion with chemotherapeutic agents in clinical trials specific to
non-small cell lung and bladder cancer [13, 14].
Pancreatic adenocarcinomas show higher levels of Hsp27
expression when compared with healthy pancreatic tissue, and
the protein can also be detected with high sensitivity in the
serum of patients with pancreatic cancer [3]. Preclinical studies
additionally show that Hsp27 expression may play a role in the
resistance of pancreatic cancer cell lines to gemcitabine [4–6].
On these bases, the current study was designed to compare
the safety and efficacy of gemcitabine and nab-paclitaxel in
combination with either apatorsen or placebo in the first-line
setting for patients with metastatic pancreatic cancer. However,
we did not observe any improvement in clinical outcomes in
the intent-to-treat population in this trial; indeed, patients on
the apatorsen arm fared numerically worse in terms of both
PFS and OS when compared with patients on the placebo con-
trol arm, although these differences were not statistically signif-
icant. The only subgroup for whom a potential benefit of
apatorsen could be identified was those patients with high
serum levels of Hsp27, a marker that portended a very poor
prognosis overall. However, the number of subjects who fit into
this category was too small, representing only 14% of the entire
study population, to draw any definitive conclusions. Further
studies, either prospectively designed trials or retrospective
analyses of available clinically annotated samples, will be
required to assess whether Hsp27 truly represents an adverse
prognostic marker in this disease.
Several additional points are worth noting. First, the clinical
outcomes for patients on both arms of this study were consid-
erably inferior to those observed on the gemcitabine plus nab-
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paclitaxel arm from the phase III MPACT trial [8], in which
patients achieved a median OS and PFS of 8.5 and 5.5 months,
respectively. It is unclear why subjects on the current study
fared so poorly, given similar demographics to the MPACT
study; nevertheless, it seems fairly unlikely that a benefit from
apatorsen would somehow be unmasked even if patients had
achieved outcomes that more similarly matched those of the
MPACT trial. Furthermore, because this study did not mandate
pretreatment collection of tumor specimens, putative tissue-
based predictive markers of apatorsen sensitivity could not be
assessed, nor could the pharmacodynamic effects of this agent
given the absence of requiring on-treatment tumor biopsies.
No consistent trendwas identified on serial serum Hsp27meas-
urements in responders versus nonresponders (data not
shown). This lack of robust correlative data represents a major
limitation of our study and highlights one of the major ongoing
challenges in pancreatic cancer trial design in general, espe-
cially when trying to confirm the putative mechanism of action
of novel targeted agents.
In conclusion, the addition of apatorsen to a standard com-
bination chemotherapy regimen in the first-line setting did not
result in improved survival or other clinically relevant endpoints
in patients with metastatic pancreatic cancer. Further studies of
this agent in unselected patients do not appear to be indicated,
although the findings from this trial do hint at the possible
prognostic and predictive value of serum Hsp27 that may war-
rant further investigation. If ASO technologies targeting this
and other cancer-related genes continue to be pursued in pan-
creatic cancer, they should ideally be evaluated in the context
of trials that mandate serial collection of both tumor and blood
samples to look for predictive markers and pharmacodynamic
markers of response, notwithstanding the clinical and logistic
hurdles these may present in this patient population.
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